Clarity confirms US-based manufacturing in response to newly announced tariff on pharmaceuticals
Sydney, Australia 26 September 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, confirms that Clarity’s Targeted Copper Theranostic (TCT) products and clinical development programs will remain unaffected by the United States’ (US) imposed 100% tariff on…